Cellosaurus cell line Hepa 1-6 (CVCL

Cellosaurus Hepa 1-6 (CVCL_0327)

[Text version]

Cell line name

Hepa 1-6

Synonyms

HEPA 1-6; Hepa-1-6; Hepa1-6

Accession

CVCL_0327

Resource Identification Initiative

To cite this cell line use: Hepa 1-6 (RRID:CVCL_0327)

Comments

Characteristics: Secretes several liver products including albumin, alpha-fetoprotein, alpha 1-antitrypin and amylase (ECACC=92110305).
Doubling time: 26.99 +- 1.93 hours (PubMed=28152020); ~30 hours (DSMZ=ACC-175).
Omics: Array-based CGH.
Omics: Deep phosphoproteome analysis.
Omics: Deep proteome analysis.
Omics: Transcriptome analysis by microarray.
Derived from site: In situ; Liver; UBERON=UBERON_0002107.

Disease

Hepatocellular carcinoma of the mouse (NCIt: C38756)

Species of origin

Mus musculus (Mouse) (NCBI Taxonomy: 10090)
Breed/subspecies: C57L/J.

Hierarchy

Parent: CVCL_S550 (Hepa-1)
Children:

CVCL_IU28 (Dt81Hepa1-6)	CVCL_C8Y7 (Hepa 1-6-Luc)	CVCL_A5BH (Hepa 1-6/10R)
CVCL_RI52 (Hepa/8F5)	CVCL_RA18 (Hepa1-6-eGFP-Puro)	CVCL_RA19 (Hepa1-6-Fluc-Neo)
CVCL_RA20 (Hepa1-6-Fluc-Neo/eGFP-Puro)	CVCL_RA21 (Hepa1-6-iRFP-Puro)	CVCL_E1L8 (HyCyte Hepa 1-6 KO-mEno1)
CVCL_D6BL (HyCyte Hepa 1-6 KO-mSlc39a1)	CVCL_E1L9 (HyCyte Hepa 1-6 KO-mTrp53)	CVCL_E3HH (HyCyte Hepa 1-6-Luc)
CVCL_B6ZC (Res1-6)	CVCL_E0V9 (Ubigene Hepa 1-6 Bcl9 KO)	CVCL_E0VA (Ubigene Hepa 1-6 C3 KO)
CVCL_E0VB (Ubigene Hepa 1-6 Clec10a KO)	CVCL_E0VC (Ubigene Hepa 1-6 Hif1a KO)	CVCL_E0VD (Ubigene Hepa 1-6 Mettl4 KO)

Sex of cell

Female

Category

Cancer cell line

STR profile

Source(s): PubMed=31220119; Ubigene=YC-A005

Markers:

Mouse STR 1-1	14,15,16
Mouse STR 1-2	13
Mouse STR 2-1	14
Mouse STR 3-2	10
Mouse STR 4-2	18.3,19.3
Mouse STR 5-5	17
Mouse STR 6-4	18,19
Mouse STR 6-7	15
Mouse STR 7-1	25.2
Mouse STR 8-1	15
Mouse STR 11-2	16
Mouse STR 12-1	17
Mouse STR 13-1	17.1
Mouse STR 15-3	17,18,19
Mouse STR 17-2	14
Mouse STR 18-3	16,17
Mouse STR 19-2	10,11
Mouse STR X-1	25

Publications

PubMed=11004682; DOI=10.1002/1097-0215(20001015)88:2<287::AID-IJC22>3.0.CO;2-U
Briz O., Serrano M.A., Macias R.I.R., Marin J.J.G.
Overcoming cisplatin resistance in vitro by a free and liposome-encapsulated bile acid derivative: BAMET-R2.
Int. J. Cancer 88:287-292(2000)

PubMed=12606785; DOI=10.1124/mol.63.3.742
Briz O., Macias R.I.R., Vallejo M., Silva A., Serrano M.A., Marin J.J.G.
Usefulness of liposomes loaded with cytostatic bile acid derivatives to circumvent chemotherapy resistance of enterohepatic tumors.
Mol. Pharmacol. 63:742-750(2003)

PubMed=25193168; DOI=10.1074/mcp.M113.037291; PMCID=PMC4256493
Hornburg D., Drepper C., Butter F., Meissner F., Sendtner M., Mann M.
Deep proteomic evaluation of primary and cell line motoneuron disease models delineates major differences in neuronal characteristics.
Mol. Cell. Proteomics 13:3410-3420(2014)

PubMed=26280412; DOI=10.1038/nbt.3327
Humphrey S.J., Azimifar S.B., Mann M.
High-throughput phosphoproteomics reveals in vivo insulin signaling dynamics.
Nat. Biotechnol. 33:990-995(2015)

PubMed=28152020; DOI=10.1371/journal.pone.0171215; PMCID=PMC5289561
Lacoste B., Raymond V.-A., Cassim S., Lapierre P., Bilodeau M.
Highly tumorigenic hepatocellular carcinoma cell line with cancer stem cell-like properties.
PLoS ONE 12:E0171215-E0171215(2017)

PubMed=31220119; DOI=10.1371/journal.pone.0218412; PMCID=PMC6586308
Almeida J.L., Dakic A., Kindig K., Kone M., Letham D.L.D., Langdon S., Peat R., Holding-Pillai J., Hall E.M., Ladd M., Shaffer M.D., Berg H., Li J.-L., Wigger G., Lund S., Steffen C.R., Fransway B.B., Geraghty B., Natoli M., Bauer B.A., Gollin S.M., Lewis D.W., Reid Y.A.
Interlaboratory study to validate a STR profiling method for intraspecies identification of mouse cell lines.
PLoS ONE 14:E0218412-E0218412(2019)

DOI=10.37421/2684-4567.2021.5.121
Azawi S., Piaszinski K., Balachandran M., Liehr T., Rincic M.
Molecular cytogenomic characterization of two murine liver cancer cell lines: MH-22A and Hepa 1-6.
J. Genet. Genomes 5:1.1-1.6(2021)

Cross-references

Cell line collections (Providers)